文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

巴雷特食管射频消融后复发的相关因素

Factors Associated With Recurrence of Barrett's Esophagus After Radiofrequency Ablation.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-06-11

这项回顾性队列研究纳入2005至2016年接受射频消融治疗的430例巴雷特食管退伍军人,其中337例达到肠化生完全根除。中位随访1.9年,98例(29.1%)复发,年复发率10.8%;基线异型增生和长段巴雷特食管增加复发风险,高容量中心治疗降低复发风险。

要点

  • 肠化生完全根除后巴雷特食管年复发率为10.8%,异型增生年发生率2.2%。
  • 基线异型增生(HR 1.71)和长段巴雷特食管(HR 1.59)与复发风险升高相关。
  • 高容量射频消融中心(第4四分位 vs 第1四分位:HR 0.19)与复发风险降低相关。

核心结论

  • 基线异型增生、长段巴雷特食管和低容量射频消融中心治疗与肠化生完全根除后巴雷特食管复发相关。
  • 作者认为这些发现提示应在高容量中心开展此类操作。

研究设计与样本

  • 回顾性队列研究,利用美国退伍军人 Affairs(VA)国家医疗系统数据,纳入2005年至2016年接受射频消融治疗并接受随访内镜检查的巴雷特食管退伍军人。
  • 共430例接受射频消融治疗,其中337例(78.4%)达到肠化生完全根除;随访至巴雷特食管复发、异型增生、死亡或2016年10月。

主要发现

  • 337例达到肠化生完全根除的患者中,98例(29.1%)在中位1.9年(总计906.0患者年)随访期间出现巴雷特食管复发,发病率为10.8%/患者年。
  • 20例(2.2%/患者年)发生异型增生,3例(0.3%/患者年)发生癌症。
  • 基线异型增生与复发风险升高相关(HR 1.71;95% CI 1.03-2.84)。
  • 长段巴雷特食管与复发风险升高相关(HR 1.59;95% CI 1.01-2.51)。
  • 在高容量射频消融中心治疗与复发风险降低相关(第4四分位 vs 第1四分位:HR 0.19;95% CI 0.05-0.68)。

临床怎么用

  • 原文结论指出这些发现提示应在高容量中心开展射频消融操作。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Radiofrequency ablation (RFA) is effective treatment for Barrett's esophagus (BE). However, some patients have recurrence after complete eradication of intestinal metaplasia (CEIM). We investigated the incidence of and factors associated with BE recurrence, with or without neoplasia, after RFA and CEIM using data from the national Veterans Affairs (VA) healthcare system. METHODS: We performed a retrospective cohort study of Veterans with BE treated by RFA from 2005 through 2016 with follow-up endoscopy. Subjects were followed until BE recurrence, neoplasia, death until October 2016. CEIM, BE recurrence, and factors associated with recurrence were identified by review of medical records. We calculated incidence rates of BE recurrence, with and without neoplasia, after CEIM and identified predictors using Cox proportional hazards models. RESULTS: We identified 430 Veterans with BE who were treated with RFA; of these 337 achieved CEIM (78.4%). Most were men (98.6%), White (83.7%), and 66.0% had baseline dysplasia. Of those with CEIM, 98 patients (29.1%) had recurrence of BE during a total 906.0 patient-years of follow-up (median 1.9 years) after CEIM (incidence, 10.8%/patient-year). Dysplasia developed in 20 patients (2.2%/patient-year) and cancer in 3 patients (0.3%/patient-year). Baseline dysplasia (hazard ratio [HR], 1.71; 95% CI, 1.03-2.84) and long-segment BE (HR, 1.59; 95% CI, 1.01-2.51) increased risk of BE recurrence whereas treatment at high-volume RFA facilities reduced risk of BE recurrence (for quartile 4 vs quartile 1: HR, 0.19; 95% CI, 0.05-0.68). CONCLUSIONS: In a nationwide VA system study of outcomes of RFA for BE, we associated baseline dysplasia, long-segment BE, and treatment at low-volume RFA centers with recurrence of BE after CEIM. The findings call for performing these procedures in high-volume centers.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Tan MC, Kanthasamy KA, Yeh AG, et al. Factors Associated With Recurrence of Barrett's Esophagus After Radiofrequency Ablation. Clin Gastroenterol Hepatol. 2018. PMID: 29902646. doi:10.1016/j.cgh.2018.05.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。